ALECTOR INC (ALEC)
US0144421072 - Common Stock
Taking everything into account, ALEC scores 3 out of 10 in our fundamental rating. ALEC was compared to 571 industry peers in the Biotechnology industry. While ALEC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ALEC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ALEC had negative earnings in the past year.
In the past year ALEC has reported a negative cash flow from operations.
ALEC had negative earnings in each of the past 5 years.
In the past 5 years ALEC reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -30.70%, ALEC is in the better half of the industry, outperforming 67.37% of the companies in the same industry.
ALEC has a Return On Equity of -133.19%. This is in the lower half of the industry: ALEC underperforms 61.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.7% | ||
| ROE | -133.19% | ||
| ROIC | N/A |
ROA(3y)-14.12%
ROA(5y)-21.26%
ROE(3y)-57.15%
ROE(5y)-59.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALEC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALEC has been increased compared to 1 year ago.
The number of shares outstanding for ALEC has been increased compared to 5 years ago.
ALEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.95, we must say that ALEC is in the distress zone and has some risk of bankruptcy.
ALEC has a Altman-Z score of -1.95. This is comparable to the rest of the industry: ALEC outperforms 53.97% of its industry peers.
ALEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.95 |
ROIC/WACCN/A
WACC10.48%
2.3 Liquidity
A Current Ratio of 3.29 indicates that ALEC has no problem at all paying its short term obligations.
ALEC has a Current ratio of 3.29. This is in the lower half of the industry: ALEC underperforms 60.67% of its industry peers.
A Quick Ratio of 3.29 indicates that ALEC has no problem at all paying its short term obligations.
ALEC has a Quick ratio of 3.29. This is comparable to the rest of the industry: ALEC outperforms 41.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 |
3. Growth
3.1 Past
ALEC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.59%.
Looking at the last year, ALEC shows a very negative growth in Revenue. The Revenue has decreased by -36.06% in the last year.
Measured over the past years, ALEC shows a very strong growth in Revenue. The Revenue has been growing by 28.50% on average per year.
EPS 1Y (TTM)-0.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.87%
Revenue 1Y (TTM)-36.06%
Revenue growth 3Y66.31%
Revenue growth 5Y28.5%
Sales Q2Q%68.43%
3.2 Future
The Earnings Per Share is expected to grow by 50.29% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 68.76% on average over the next years. This is a very strong growth
EPS Next Y-23.3%
EPS Next 2Y0.9%
EPS Next 3Y1.96%
EPS Next 5Y50.29%
Revenue Next Year-31.43%
Revenue Next 2Y22.51%
Revenue Next 3Y14.29%
Revenue Next 5Y68.76%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALEC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALEC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.9%
EPS Next 3Y1.96%
5. Dividend
5.1 Amount
No dividends for ALEC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALECTOR INC
NASDAQ:ALEC (11/25/2024, 7:59:19 PM)
After market: 2.99 -0.97 (-24.49%)3.96
+0.02 (+0.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap387.80M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.7% | ||
| ROE | -133.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-0.59%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-23.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-36.06%
Revenue growth 3Y66.31%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y